Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 191, Issue , 2015, Pages 138-148

  Ip, Chi Kin ^a,b   Jin, Dong Mei ^a   Gao, Jia Jia ^a,b,c   Meng, Zhe ^a   Meng, Jing ^d   Tan, Zhi ^e   Wang, Jing Feng ^a,b   Geng, Deng Feng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology   (China)

^c Shenzhen Sun Yi xian Cardiovascular Hospital   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cardiovascular events; Cholesteryl ester transfer protein inhibitor; Ezetimibe; Fibrate; n 3 fatty acid; Niacin; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATINE KINASE; DALCETRAPIB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; LIPID;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; DRUG TREATMENT FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER INJURY; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; LIPID METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84936978313     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.228     Document Type: Article

References (38)

1. National Heart Lung, and Blood Institute. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases 2012 US Department of Health and Human Services, National Institutes of Health Bethesda, MD
2. L.S. Lim, N. Haq, S. Mahmood, and et al. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice Am. J. Prev. Med. 40 3 2011 381.e1 381.e10
3. A.S. Go, D. Mozaffarian, V.L. Roger, and et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association Circulation 129 3 2014 e28 e292
4. D.J. Gordon, J.L. Probstfield, R.J. Garrison, and et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1 1989 8 15
5. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 9753 2010 1670 1681
6. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011
7. S.E. Nissen, J.C. Tardif, S.J. Nicholls, and et al. Effect of torcetrapib on the progression of coronary atherosclerosis N. Engl. J. Med. 356 13 2007 1304 1316
8. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 21 2007 2109 2122
9. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 22 2012 2089 2099
10. A.I.M.-H.I.G.H. Investigators, W.E. Boden, J.L. Probstfield, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 24 2011 2255 2267
11. HPS2-THRIVE Collaborative Group M.J. Landray, R. Haynes, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N. Engl. J. Med. 371 3 2014 203 212
12. A.J. Taylor, L.E. Sullenberger, H.J. Lee, and et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 23 2004 3512 3517
13. Group AS, H.N. Ginsberg, M.B. Elam, and et al. Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 362 17 2010 1563 1574
14. M. Yokoyama, H. Origasa, M. Matsuzaki, and et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 9567 2007 1090 1098
15. D. Kromhout, E.J. Giltay, and J.M. Geleijnse Alpha Omega Trial Group. n - 3 fatty acids and cardiovascular events after myocardial infarction N. Engl. J. Med. 363 21 2010 2015 2026
16. J.J. Kastelein, F. Akdim, E.S. Stroes, and et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia N. Engl. J. Med. 358 14 2008 1431 1443
17. C.P. Cannon IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin vs simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes Late Breaking Session Presented at AHA 2014 November 17, 2014
18. P.J. Barter, and J.J. Kastelein Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease J. Am. Coll. Cardiol. 47 3 2006 492 499
19. J.C. Tardif, J. Gregoire, P.L. L'Allier, and et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 15 2007 1675 1682
20. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, and et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 17 2003 2292 2300
21. M. Briel, I. Ferreira-Gonzalez, J.J. You, and et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
22. B.F. Voight, G.M. Peloso, M. Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 9841 2012 572 580
23. H. Rubins, S. Robins, D. Collins, and et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N. Engl. J. Med. 341 6 1999 410 418
24. The bezafibrate infarction prevention (BIP) study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease Circulation 102 1 2000 21 27
25. A. Keech, R.J. Simes, P. Barter, and et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 9500 2005 1849 1861
26. F. Valagussa, M.G. Franzosi, E. Geraci, and et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 9177 1999 447 455
27. K. Musa-Veloso, M.A. Binns, A. Kocenas, and et al. Impact of low v. moderate intakes of long-chain n - 3 fatty acids on risk of coronary heart disease Br. J. Nutr. 106 8 2011 1129 1141
28. N. Sarwar, J. Danesh, G. Eiriksdottir, and et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 4 2007 450 458
29. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 18 2009 1993 2000
30. M. Miller, N.J. Stone, C. Ballantyne, and et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 20 2011 2292 2333
31. H.R. Davis Jr., L.J. Zhu, L.M. Hoos, and et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis J. Biol. Chem. 279 32 2004 33586 33592
32. Myocardial Infarction Genetics Consortium Investigators, N.O. Stitziel, H.H. Won, and et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease N. Engl. J. Med. 371 22 2014 2072 2082
33. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl. 2 2014 S1 S45
34. B.A. Ference, W. Yoo, I. Alesh, and et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J. Am. Coll. Cardiol. 60 25 2012 2631 2639
35. T.A. Lagace PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells Curr. Opin. Lipidol. 25 5 2014 387 393
36. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N. Engl. J. Med. 354 12 2006 1264 1272
37. J.G. Robinson, B.S. Nedergaard, W.J. Rogers, and et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 18 2014 1870 1882
38. ClinicalTrials.gov Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) NCT01764633 http://clinicaltrials.gov/ct2/show/NCT01764633 (Accessed March 1, 2015)